

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010

## **UNCX RABBIT PAB**

Cat.#: S221588

Product Name: Anti-UNCX Rabbit Polyclonal Antibody

Synonyms: UNCX4.1

UNIPROT ID: A6NJT0 (Gene Accession - NP\_001073930)

**Background:** UNCX (UNC homeobox), also known as UNCX4.1, is a 531 amino acid nuclear transcription factor involved in neurogenesis and somitogenesis. Containing one homeobox DNA-binding domain, UNCX belongs to the paired homeobox family and UNC4 subfamily. UNCX assists in the formation of connections between hypothalamic neurons and the pituitary, which is necessary for central neurons to deliver hormones into peripheral blood. UNCX also plays a role in maintaining differentiation of the axial skeleton and acts upstream of Pax-9. The gene encoding UNCX maps to human chromosome 7, which houses over 1,000 genes and comprises nearly 5% of the human genome. Chromosome 7 has been linked to Osteogenesis imperfecta, Pendred syndrome, Lissencephaly, Citrullinemia and Shwachman-Diamond syndrome.

**Immunogen:** Synthetic peptide of human UNCX

**Applications:** ELISA, IHC

**Recommended Dilutions:** IHC: 25-100; ELISA: 5000-10000

Host Species: Rabbit

**Clonality:** Rabbit Polyclonal


**Isotype:** Immunogen-specific rabbit IgG **Purification:** Antigen affinity purification **Species Reactivity:** Human, Mouse

Constituents: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40%


glycerol

**Research Areas:** Epigenetics and Nuclear Signaling, Neuroscience

Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing



Immunohistochemistry analysis of paraffin embedded Human colorectal cancer tissue using 221588 (UNCX Antibody) at a dilution of 1/25 (Nucleus).



In comparision with the IHC on the left, the same paraffin-embedded Human colorectal cancer tissue is first treated with the synthetic peptide and then with 221588(Anti-UNCX Antibody) at dilution 1/25.



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010